Evaluation of the results of the conventional methods of treatment of bronchogenic carcinoma by surgical excision and irradiation during the past 50 years has indicated the need for more effective therapy. During the last decade the possibility of discovering a preparation that might serve as an adjunct in the treatment of neoplastic disease has been viewed with increasing interest. Consequently, an intensive search has been made for a chemical that would have a selective, yet lethal, effect on the neoplastic cell. As a result of this search, a group of cytotoxic chemical agents has been discovered that has proved promising. One of these, nitrogen mustard (methyl-bis [β-chloroethyl] amine), was first utilized in the treatment of neoplastic disease by Gilman and co-workers in 1943. Since then, frequent reports concerning its use in patients with advanced bronchogenic carcinoma have appeared in the literature. Our experience with this chemical in 198 patients with
Hatch HB, Bradford JK, Ochsner A. NITROGEN MUSTARD IN TREATMENT OF ADVANCED CARCINOMA OF LUNGANALYSIS OF ONE HUNDRED NINETY-EIGHT CASES. JAMA. 1956;160(13):1129–1130. doi:10.1001/jama.1956.02960480029008
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: